KR20190086772A - 벤젠술폰아미드 화합물 및 치료제로서의 그의 용도 - Google Patents
벤젠술폰아미드 화합물 및 치료제로서의 그의 용도 Download PDFInfo
- Publication number
- KR20190086772A KR20190086772A KR1020197019389A KR20197019389A KR20190086772A KR 20190086772 A KR20190086772 A KR 20190086772A KR 1020197019389 A KR1020197019389 A KR 1020197019389A KR 20197019389 A KR20197019389 A KR 20197019389A KR 20190086772 A KR20190086772 A KR 20190086772A
- Authority
- KR
- South Korea
- Prior art keywords
- benzenesulfonamide
- amino
- thiazol
- chloro
- fluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 CC(C)(C)OC(N(c1c[s]cn1)S(c(c(F)cc(N(C1)C(OC(C)(C)C)=*c2c1c(CO)ccc2)c1)c1F)(=O)=O)=O Chemical compound CC(C)(C)OC(N(c1c[s]cn1)S(c(c(F)cc(N(C1)C(OC(C)(C)C)=*c2c1c(CO)ccc2)c1)c1F)(=O)=O)=O 0.000 description 3
- HBBSMJFEJAGCAU-HNNXBMFYSA-N CC[C@@H](c1ccccc1F)Nc(cc(c(S(Nc1ncc[s]1)(=O)=O)c1)F)c1Cl Chemical compound CC[C@@H](c1ccccc1F)Nc(cc(c(S(Nc1ncc[s]1)(=O)=O)c1)F)c1Cl HBBSMJFEJAGCAU-HNNXBMFYSA-N 0.000 description 2
- UEUXSRWWPHWLLL-UHFFFAOYSA-N Cc(c(S(Nc1c[s]cn1)(=O)=O)c1F)cc(NCc2c(CN3CCC3)cccc2)c1F Chemical compound Cc(c(S(Nc1c[s]cn1)(=O)=O)c1F)cc(NCc2c(CN3CCC3)cccc2)c1F UEUXSRWWPHWLLL-UHFFFAOYSA-N 0.000 description 2
- WNECGPWQNUOQSV-UHFFFAOYSA-N O=S(c(c(F)cc(NCc1c(CCN(C2)CC2F)cccc1)c1)c1F)(Nc1c[s]cn1)=O Chemical compound O=S(c(c(F)cc(NCc1c(CCN(C2)CC2F)cccc1)c1)c1F)(Nc1c[s]cn1)=O WNECGPWQNUOQSV-UHFFFAOYSA-N 0.000 description 2
- INXZFSBJIFRDFR-UHFFFAOYSA-N CC(C)(C)N(C)Cc(cccc1F)c1C#N Chemical compound CC(C)(C)N(C)Cc(cccc1F)c1C#N INXZFSBJIFRDFR-UHFFFAOYSA-N 0.000 description 1
- FMMLMJSMKQIYRR-UHFFFAOYSA-N CC(C)(C)N(C)Cc1cccc(F)c1CNc(cc1F)cc(F)c1S(N(C(OC(C)(C)C)=O)c1c[s]cn1)(=O)=O Chemical compound CC(C)(C)N(C)Cc1cccc(F)c1CNc(cc1F)cc(F)c1S(N(C(OC(C)(C)C)=O)c1c[s]cn1)(=O)=O FMMLMJSMKQIYRR-UHFFFAOYSA-N 0.000 description 1
- PGRPJMHWXNHSNI-UHFFFAOYSA-N CC(C)(C)OC(N(Cc1c(CO)c(F)ccc1F)c(c(Cl)c1)cc(F)c1S(Nc1c[s]cn1)(=O)=O)=O Chemical compound CC(C)(C)OC(N(Cc1c(CO)c(F)ccc1F)c(c(Cl)c1)cc(F)c1S(Nc1c[s]cn1)(=O)=O)=O PGRPJMHWXNHSNI-UHFFFAOYSA-N 0.000 description 1
- NHUZAYLSBPZZIM-UHFFFAOYSA-N CC(C)(C)OC(N(c1c[s]cn1)S(c(c(F)c(C)c(NCc(c(CN1CCC1)ccc1)c1F)c1)c1F)(=O)=O)=O Chemical compound CC(C)(C)OC(N(c1c[s]cn1)S(c(c(F)c(C)c(NCc(c(CN1CCC1)ccc1)c1F)c1)c1F)(=O)=O)=O NHUZAYLSBPZZIM-UHFFFAOYSA-N 0.000 description 1
- UBZAKRBTDAHJGA-UHFFFAOYSA-N CC(C)(C)OC(N(c1c[s]cn1)S(c(c(F)c1F)ccc1NCc(c(CN1CCC1)c(cc1)F)c1F)(=O)=O)=O Chemical compound CC(C)(C)OC(N(c1c[s]cn1)S(c(c(F)c1F)ccc1NCc(c(CN1CCC1)c(cc1)F)c1F)(=O)=O)=O UBZAKRBTDAHJGA-UHFFFAOYSA-N 0.000 description 1
- NKNKCQWIPNHIHP-UHFFFAOYSA-N CC(C)(C)OC(N(c1c[s]cn1)S(c(c(F)cc(F)c1F)c1F)(=O)=O)=O Chemical compound CC(C)(C)OC(N(c1c[s]cn1)S(c(c(F)cc(F)c1F)c1F)(=O)=O)=O NKNKCQWIPNHIHP-UHFFFAOYSA-N 0.000 description 1
- HYPMPMSWXBAMGV-UHFFFAOYSA-N CC(C)(C)OC(N(c1c[s]cn1)S(c(c(F)cc(NCc1c(CN2CCC2)c(F)ccc1Cl)c1)c1F)(=O)=O)=O Chemical compound CC(C)(C)OC(N(c1c[s]cn1)S(c(c(F)cc(NCc1c(CN2CCC2)c(F)ccc1Cl)c1)c1F)(=O)=O)=O HYPMPMSWXBAMGV-UHFFFAOYSA-N 0.000 description 1
- ZBIRXLLUEXOPSH-LJQANCHMSA-N CC(C)(C)OC(N(c1c[s]cn1)S(c(c(F)cc(N[C@H](c1cc(Cl)ccc1F)N)c1)c1F)(=O)=O)=O Chemical compound CC(C)(C)OC(N(c1c[s]cn1)S(c(c(F)cc(N[C@H](c1cc(Cl)ccc1F)N)c1)c1F)(=O)=O)=O ZBIRXLLUEXOPSH-LJQANCHMSA-N 0.000 description 1
- YYZWJJKIWKJFKG-UHFFFAOYSA-N CC(C)(C)OC(N(c1c[s]cn1)S(c(cc(C)c(NCc1c(C)cccc1C)c1)c1F)(=O)=O)=O Chemical compound CC(C)(C)OC(N(c1c[s]cn1)S(c(cc(C)c(NCc1c(C)cccc1C)c1)c1F)(=O)=O)=O YYZWJJKIWKJFKG-UHFFFAOYSA-N 0.000 description 1
- KXVNJCDHFJAKRU-UHFFFAOYSA-N CC(C)(C)OC(N(c1c[s]cn1)S(c(cc(c(NCc1c(CN(C2)CC2F)cccc1F)c1)Cl)c1F)(=O)=O)=O Chemical compound CC(C)(C)OC(N(c1c[s]cn1)S(c(cc(c(NCc1c(CN(C2)CC2F)cccc1F)c1)Cl)c1F)(=O)=O)=O KXVNJCDHFJAKRU-UHFFFAOYSA-N 0.000 description 1
- FQXRLMBEPRDFFM-LJQANCHMSA-N CC(C)(C)OC(N(c1c[s]cn1)S(c(cc(c(N[C@H](c1cc(Br)ccc1)N)c1)Cl)c1F)(=O)=O)=O Chemical compound CC(C)(C)OC(N(c1c[s]cn1)S(c(cc(c(N[C@H](c1cc(Br)ccc1)N)c1)Cl)c1F)(=O)=O)=O FQXRLMBEPRDFFM-LJQANCHMSA-N 0.000 description 1
- UQBMFNQLQGQQRW-OAQYLSRUSA-N CC(C)(C)OC(N(c1c[s]cn1)S(c(cc(c(N[C@H](c1cc(C=C)ccc1F)N)c1)Cl)c1F)(=O)=O)=O Chemical compound CC(C)(C)OC(N(c1c[s]cn1)S(c(cc(c(N[C@H](c1cc(C=C)ccc1F)N)c1)Cl)c1F)(=O)=O)=O UQBMFNQLQGQQRW-OAQYLSRUSA-N 0.000 description 1
- GMBQMUZBHHLINN-UHFFFAOYSA-N CC(C)(C)OC(N(c1n[o]cc1)S(c(c(F)cc(F)c1)c1F)(=O)=O)=O Chemical compound CC(C)(C)OC(N(c1n[o]cc1)S(c(c(F)cc(F)c1)c1F)(=O)=O)=O GMBQMUZBHHLINN-UHFFFAOYSA-N 0.000 description 1
- ZZASDGGTFRBRED-UHFFFAOYSA-N CC(C)(C)OC(NCc(c(CN1CCC1)ccc1)c1F)=O Chemical compound CC(C)(C)OC(NCc(c(CN1CCC1)ccc1)c1F)=O ZZASDGGTFRBRED-UHFFFAOYSA-N 0.000 description 1
- PKLOOHYWEVIZIK-VGOFMYFVSA-N CC(C)(C)S(/N=C/c(c(F)ccc1)c1F)=O Chemical compound CC(C)(C)S(/N=C/c(c(F)ccc1)c1F)=O PKLOOHYWEVIZIK-VGOFMYFVSA-N 0.000 description 1
- HYBODUMJZBZPQW-VGOFMYFVSA-N CC(C)(C)S(/N=C/c1cc(Br)ccc1F)=O Chemical compound CC(C)(C)S(/N=C/c1cc(Br)ccc1F)=O HYBODUMJZBZPQW-VGOFMYFVSA-N 0.000 description 1
- YYYFGTCIQFUVEZ-DDYRAIOVSA-N CC(C)(C)[S@@](/N=C(\C(F)(F)F)/c(cccc1)c1F)=O Chemical compound CC(C)(C)[S@@](/N=C(\C(F)(F)F)/c(cccc1)c1F)=O YYYFGTCIQFUVEZ-DDYRAIOVSA-N 0.000 description 1
- KEXYFKBTLGWXOQ-JYWRCUDFSA-N CC(C)(C)[S@@](/N=C(\C(F)(F)F)/c1cc(Cl)ccc1F)=O Chemical compound CC(C)(C)[S@@](/N=C(\C(F)(F)F)/c1cc(Cl)ccc1F)=O KEXYFKBTLGWXOQ-JYWRCUDFSA-N 0.000 description 1
- OTJRYGGQVXUWCX-DGIBIBHMSA-N CC(C)(C)[S@@](N[C@@H](C(F)(F)F)c(cccc1)c1F)=O Chemical compound CC(C)(C)[S@@](N[C@@H](C(F)(F)F)c(cccc1)c1F)=O OTJRYGGQVXUWCX-DGIBIBHMSA-N 0.000 description 1
- RPJIQAVCHUUEID-UHFFFAOYSA-N CC1(C)N(Cc2c(CN)cccc2)CC1 Chemical compound CC1(C)N(Cc2c(CN)cccc2)CC1 RPJIQAVCHUUEID-UHFFFAOYSA-N 0.000 description 1
- ZJXAVOQIBGVXBS-UHFFFAOYSA-N CCC(c1ccncc1)Nc(cc(c(S(Nc1ncc[s]1)(=O)=O)c1)F)c1Cl Chemical compound CCC(c1ccncc1)Nc(cc(c(S(Nc1ncc[s]1)(=O)=O)c1)F)c1Cl ZJXAVOQIBGVXBS-UHFFFAOYSA-N 0.000 description 1
- KUSOKGVIMNZQLH-KRWDZBQOSA-N CC[C@@H](c1cc(F)ccc1Cl)Nc(cc1F)cc(F)c1S(Nc1ccncn1)(=O)=O Chemical compound CC[C@@H](c1cc(F)ccc1Cl)Nc(cc1F)cc(F)c1S(Nc1ccncn1)(=O)=O KUSOKGVIMNZQLH-KRWDZBQOSA-N 0.000 description 1
- NPGAXSHDDOESHB-JTQLQIEISA-N CN(C)C[C@@H](c1ccccc1)N Chemical compound CN(C)C[C@@H](c1ccccc1)N NPGAXSHDDOESHB-JTQLQIEISA-N 0.000 description 1
- ARJVIRXMXFEDMV-KRWDZBQOSA-N CN(C)C[C@@H](c1ccccc1)Nc(cc(c(S(Nc1ncc[s]1)(=O)=O)c1)F)c1Cl Chemical compound CN(C)C[C@@H](c1ccccc1)Nc(cc(c(S(Nc1ncc[s]1)(=O)=O)c1)F)c1Cl ARJVIRXMXFEDMV-KRWDZBQOSA-N 0.000 description 1
- RRYGKDXHFGRNET-UHFFFAOYSA-N CN(Cc(c(CN1CCC1)c(cc1)F)c1F)c(cc1F)cc(F)c1S(Nc1c[s]cn1)(=O)=O Chemical compound CN(Cc(c(CN1CCC1)c(cc1)F)c1F)c(cc1F)cc(F)c1S(Nc1c[s]cn1)(=O)=O RRYGKDXHFGRNET-UHFFFAOYSA-N 0.000 description 1
- AZWNYAOLCKLXKJ-XMMPIXPASA-N COc1cc(OC)c(CN(c([s]2)ncc2Cl)S(c(cc(c(N[C@H](c(cccc2)c2F)N)c2)Cl)c2F)(=O)=O)cc1 Chemical compound COc1cc(OC)c(CN(c([s]2)ncc2Cl)S(c(cc(c(N[C@H](c(cccc2)c2F)N)c2)Cl)c2F)(=O)=O)cc1 AZWNYAOLCKLXKJ-XMMPIXPASA-N 0.000 description 1
- KSHFHXDVFOGIJJ-UHFFFAOYSA-N COc1cc(OC)c(CN(c2nc(F)ccc2)S(c(c(F)c2)cc(Cl)c2NCc2cccc3ccncc23)(=O)=O)cc1 Chemical compound COc1cc(OC)c(CN(c2nc(F)ccc2)S(c(c(F)c2)cc(Cl)c2NCc2cccc3ccncc23)(=O)=O)cc1 KSHFHXDVFOGIJJ-UHFFFAOYSA-N 0.000 description 1
- KVCRECONBOQPQS-UHFFFAOYSA-N COc1cc(OC)c(CN(c2ncncc2)S(c(c(F)c2Cl)ccc2F)(=O)=O)cc1 Chemical compound COc1cc(OC)c(CN(c2ncncc2)S(c(c(F)c2Cl)ccc2F)(=O)=O)cc1 KVCRECONBOQPQS-UHFFFAOYSA-N 0.000 description 1
- KMSGTFJXYAMHCD-AREMUKBSSA-N COc1cc(OC)c(CN(c2ncncc2)S(c(c(F)cc(N[C@H](c2cc(Cl)ccc2F)N)c2)c2F)(=O)=O)cc1 Chemical compound COc1cc(OC)c(CN(c2ncncc2)S(c(c(F)cc(N[C@H](c2cc(Cl)ccc2F)N)c2)c2F)(=O)=O)cc1 KMSGTFJXYAMHCD-AREMUKBSSA-N 0.000 description 1
- GLNXZIMJUIBMSP-UHFFFAOYSA-N COc1cc(OC)c(CN(c2ncncc2)S(c(cc(c(NC2(CC2)c(cc(cc2)F)c2F)c2)Cl)c2F)(=O)=O)cc1 Chemical compound COc1cc(OC)c(CN(c2ncncc2)S(c(cc(c(NC2(CC2)c(cc(cc2)F)c2F)c2)Cl)c2F)(=O)=O)cc1 GLNXZIMJUIBMSP-UHFFFAOYSA-N 0.000 description 1
- NJFIRLLSCFWDBH-UHFFFAOYSA-N COc1ccc(CN(c2ccccn2)S(c(c(F)cc(NCc2c(CN3CCC3)cccc2F)c2)c2F)(=O)=O)c(OC)c1 Chemical compound COc1ccc(CN(c2ccccn2)S(c(c(F)cc(NCc2c(CN3CCC3)cccc2F)c2)c2F)(=O)=O)c(OC)c1 NJFIRLLSCFWDBH-UHFFFAOYSA-N 0.000 description 1
- ILYJFLNCYYQFLV-UHFFFAOYSA-N COc1ccc(CN(c2ncc[o]2)S(c(cc(c(F)c2)Cl)c2F)(=O)=O)cc1 Chemical compound COc1ccc(CN(c2ncc[o]2)S(c(cc(c(F)c2)Cl)c2F)(=O)=O)cc1 ILYJFLNCYYQFLV-UHFFFAOYSA-N 0.000 description 1
- ZTDVMZAADAEXQK-UHFFFAOYSA-N COc1ccc(CN(c2ncc[s]2)S(c(c(F)c2)cc(Cl)c2NC2(CC2)c2ccccc2F)(=O)=O)c(OC)c1 Chemical compound COc1ccc(CN(c2ncc[s]2)S(c(c(F)c2)cc(Cl)c2NC2(CC2)c2ccccc2F)(=O)=O)c(OC)c1 ZTDVMZAADAEXQK-UHFFFAOYSA-N 0.000 description 1
- FMCHIMRRVUHDDM-AREMUKBSSA-N COc1ccc(CN(c2ncc[s]2)S(c(c(F)c2)cc(Cl)c2N[C@H](CN(C2)CC2F)c2ccccc2)(=O)=O)c(OC)c1 Chemical compound COc1ccc(CN(c2ncc[s]2)S(c(c(F)c2)cc(Cl)c2N[C@H](CN(C2)CC2F)c2ccccc2)(=O)=O)c(OC)c1 FMCHIMRRVUHDDM-AREMUKBSSA-N 0.000 description 1
- RYFFMVZKEYJLHW-XMMPIXPASA-N COc1ccc(CN(c2ncc[s]2)S(c(cc2Cl)ccc2N[C@H](c2ccccc2F)N)(=O)=O)c(OC)c1 Chemical compound COc1ccc(CN(c2ncc[s]2)S(c(cc2Cl)ccc2N[C@H](c2ccccc2F)N)(=O)=O)c(OC)c1 RYFFMVZKEYJLHW-XMMPIXPASA-N 0.000 description 1
- LYKHJQWZCXZBTG-UHFFFAOYSA-N COc1ccc(CNc2ncccn2)c(OC)c1 Chemical compound COc1ccc(CNc2ncccn2)c(OC)c1 LYKHJQWZCXZBTG-UHFFFAOYSA-N 0.000 description 1
- MQKPQRMVSBHRRN-JTQLQIEISA-N C[C@@H](c(cc(CC(F)F)cc1)c1F)Nc(cc(c(S(Nc1c[s]cn1)(=O)=O)c1)F)c1Cl Chemical compound C[C@@H](c(cc(CC(F)F)cc1)c1F)Nc(cc(c(S(Nc1c[s]cn1)(=O)=O)c1)F)c1Cl MQKPQRMVSBHRRN-JTQLQIEISA-N 0.000 description 1
- ZZJJTCROAZJVLE-LBPRGKRZSA-N C[C@@H](c(cc(cc1)Br)c1F)Nc(cc(c(S(N(C(OC(C)(C)C)=O)c1c[s]cn1)(=O)=O)c1)F)c1Cl Chemical compound C[C@@H](c(cc(cc1)Br)c1F)Nc(cc(c(S(N(C(OC(C)(C)C)=O)c1c[s]cn1)(=O)=O)c1)F)c1Cl ZZJJTCROAZJVLE-LBPRGKRZSA-N 0.000 description 1
- RTNMWZVZTUEBOM-CLBCNEFWSA-N C[C@@H](c(cc(cc1)Cl)c1F)NS(C(C)(C)C)=O Chemical compound C[C@@H](c(cc(cc1)Cl)c1F)NS(C(C)(C)C)=O RTNMWZVZTUEBOM-CLBCNEFWSA-N 0.000 description 1
- NDADGHGYZVIGBP-VIFPVBQESA-N C[C@@H](c(cc(cc1)F)c1F)Nc(cc1F)cc(F)c1S(Nc1n[o]cc1)(=O)=O Chemical compound C[C@@H](c(cc(cc1)F)c1F)Nc(cc1F)cc(F)c1S(Nc1n[o]cc1)(=O)=O NDADGHGYZVIGBP-VIFPVBQESA-N 0.000 description 1
- HETXLTWAMGGCCX-INIZCTEOSA-N C[C@@H](c(cccc1)c1F)Oc(cc(c(S(N(Cc(ccc(OC)c1)c1OC)c1ncc[s]1)(=O)=O)c1)F)c1F Chemical compound C[C@@H](c(cccc1)c1F)Oc(cc(c(S(N(Cc(ccc(OC)c1)c1OC)c1ncc[s]1)(=O)=O)c1)F)c1F HETXLTWAMGGCCX-INIZCTEOSA-N 0.000 description 1
- XTMHCQKSYUDEEU-LBPRGKRZSA-N C[C@@H](c1cc(Cl)ccc1F)Nc(cc(c(S(N(C(OC(C)(C)C)=O)c1c[s]cn1)(=O)=O)c1)F)c1Cl Chemical compound C[C@@H](c1cc(Cl)ccc1F)Nc(cc(c(S(N(C(OC(C)(C)C)=O)c1c[s]cn1)(=O)=O)c1)F)c1Cl XTMHCQKSYUDEEU-LBPRGKRZSA-N 0.000 description 1
- HRQWXIVVWVETIK-KRWDZBQOSA-N C[C@@H](c1cc(F)ccc1F)Nc(c(C(F)(F)F)c1)ccc1S(N(Cc(ccc(OC)c1)c1OC)c1ncncc1)(=O)=O Chemical compound C[C@@H](c1cc(F)ccc1F)Nc(c(C(F)(F)F)c1)ccc1S(N(Cc(ccc(OC)c1)c1OC)c1ncncc1)(=O)=O HRQWXIVVWVETIK-KRWDZBQOSA-N 0.000 description 1
- KLWKJFRXLGLTIH-VIFPVBQESA-N C[C@@H](c1cc(F)ccc1F)Nc(c(Cl)c1)cc(F)c1S(Nc1c[s]cn1)(=O)=O Chemical compound C[C@@H](c1cc(F)ccc1F)Nc(c(Cl)c1)cc(F)c1S(Nc1c[s]cn1)(=O)=O KLWKJFRXLGLTIH-VIFPVBQESA-N 0.000 description 1
- MLAOKLQQAYAPLO-NSHDSACASA-N C[C@@H](c1cc(F)ccc1F)Nc(cc1)c(C(F)(F)F)cc1S(Nc1ncncc1)(=O)=O Chemical compound C[C@@H](c1cc(F)ccc1F)Nc(cc1)c(C(F)(F)F)cc1S(Nc1ncncc1)(=O)=O MLAOKLQQAYAPLO-NSHDSACASA-N 0.000 description 1
- WWNIZWZDIDUCCO-JTQLQIEISA-N C[C@@H](c1cccc(F)c1CN(C(c1ccccc11)=O)C1=O)N Chemical compound C[C@@H](c1cccc(F)c1CN(C(c1ccccc11)=O)C1=O)N WWNIZWZDIDUCCO-JTQLQIEISA-N 0.000 description 1
- NAUDJLBKIFQXDQ-WLRWDXFRSA-N C[C@@H](c1cccc2ccncc12)N[S@](C(C)(C)C)=O Chemical compound C[C@@H](c1cccc2ccncc12)N[S@](C(C)(C)C)=O NAUDJLBKIFQXDQ-WLRWDXFRSA-N 0.000 description 1
- SAMSYCPCHQYNKT-JTQLQIEISA-N C[C@@H](c1ccccc1Cl)Oc(cc(c(S(Nc1c[s]cn1)(=O)=O)c1)F)c1Cl Chemical compound C[C@@H](c1ccccc1Cl)Oc(cc(c(S(Nc1c[s]cn1)(=O)=O)c1)F)c1Cl SAMSYCPCHQYNKT-JTQLQIEISA-N 0.000 description 1
- ZMQLDSIYQUQULQ-CYBMUJFWSA-N C[C@H](c1cccc(F)c1CN(C(c1c2cccc1)=O)C2=O)N1CCC1 Chemical compound C[C@H](c1cccc(F)c1CN(C(c1c2cccc1)=O)C2=O)N1CCC1 ZMQLDSIYQUQULQ-CYBMUJFWSA-N 0.000 description 1
- KBLIOLOEZADQDG-LLVKDONJSA-N C[C@H](c1ccccc1)Nc(c(Cl)c1)cc(F)c1S(Nc1ncc[s]1)(=O)=O Chemical compound C[C@H](c1ccccc1)Nc(c(Cl)c1)cc(F)c1S(Nc1ncc[s]1)(=O)=O KBLIOLOEZADQDG-LLVKDONJSA-N 0.000 description 1
- VWVGBEKGBIGDSQ-UHFFFAOYSA-N C[Si+](C)(C)CCOCN(c1cccnn1)S(c(c(F)c1)cc(Cl)c1F)(=O)=O Chemical compound C[Si+](C)(C)CCOCN(c1cccnn1)S(c(c(F)c1)cc(Cl)c1F)(=O)=O VWVGBEKGBIGDSQ-UHFFFAOYSA-N 0.000 description 1
- OCFYIALEVMSDTJ-UHFFFAOYSA-N C[Si](C)(C)CCOCN(c1n[o]cc1)S(c(cc(c(NCc1c(CN2CCC2)cccc1)c1)Cl)c1F)(=O)=O Chemical compound C[Si](C)(C)CCOCN(c1n[o]cc1)S(c(cc(c(NCc1c(CN2CCC2)cccc1)c1)Cl)c1F)(=O)=O OCFYIALEVMSDTJ-UHFFFAOYSA-N 0.000 description 1
- VKXGNHHZKANJHU-UHFFFAOYSA-N Cc(c(F)c(c(F)c1)S(Nc2ncn[s]2)(=O)=O)c1NCc1ccccc1CN1CCC1 Chemical compound Cc(c(F)c(c(F)c1)S(Nc2ncn[s]2)(=O)=O)c1NCc1ccccc1CN1CCC1 VKXGNHHZKANJHU-UHFFFAOYSA-N 0.000 description 1
- CBHHQGVSFSVCOU-UHFFFAOYSA-N Cc(c(NCc(c(CN1CCC1)c(cc1)F)c1Cl)cc(F)c1S(Nc2c[s]cn2)(=O)=O)c1F Chemical compound Cc(c(NCc(c(CN1CCC1)c(cc1)F)c1Cl)cc(F)c1S(Nc2c[s]cn2)(=O)=O)c1F CBHHQGVSFSVCOU-UHFFFAOYSA-N 0.000 description 1
- YPFRPFIEGYHTBA-UHFFFAOYSA-N Cc(cc(c(F)c1)S(N(Cc(cc2)ccc2OC)c2n[o]cc2)(=O)=O)c1NCc1c(CN2CCC2)cccc1F Chemical compound Cc(cc(c(F)c1)S(N(Cc(cc2)ccc2OC)c2n[o]cc2)(=O)=O)c1NCc1c(CN2CCC2)cccc1F YPFRPFIEGYHTBA-UHFFFAOYSA-N 0.000 description 1
- AMLUQROOCAKVOG-UHFFFAOYSA-N Cc1cc(NCc(ccc(OC)c2)c2OC)nc(Cl)n1 Chemical compound Cc1cc(NCc(ccc(OC)c2)c2OC)nc(Cl)n1 AMLUQROOCAKVOG-UHFFFAOYSA-N 0.000 description 1
- DOHVMOVJARBHAJ-UHFFFAOYSA-N N#Cc1cc(CC=O)ccc1F Chemical compound N#Cc1cc(CC=O)ccc1F DOHVMOVJARBHAJ-UHFFFAOYSA-N 0.000 description 1
- ZEDNCCODZWRRSV-UHFFFAOYSA-N N#Cc1cccc(F)c1CN1CCC1 Chemical compound N#Cc1cccc(F)c1CN1CCC1 ZEDNCCODZWRRSV-UHFFFAOYSA-N 0.000 description 1
- SCGAWGKFOJSSOP-UHFFFAOYSA-N NC(c(cc(C(F)F)cc1)c1F)N Chemical compound NC(c(cc(C(F)F)cc1)c1F)N SCGAWGKFOJSSOP-UHFFFAOYSA-N 0.000 description 1
- QMLGCMLXNYEVPC-UHFFFAOYSA-N NC(c1cc(OC(F)F)ccc1F)N Chemical compound NC(c1cc(OC(F)F)ccc1F)N QMLGCMLXNYEVPC-UHFFFAOYSA-N 0.000 description 1
- PORPPSWKDCRHNR-UHFFFAOYSA-N NCc(cc(CCN(C1)CC1F)cc1)c1F Chemical compound NCc(cc(CCN(C1)CC1F)cc1)c1F PORPPSWKDCRHNR-UHFFFAOYSA-N 0.000 description 1
- PFEQBDPYUCBUMS-UHFFFAOYSA-N NCc(cc(CN1CCC1)cc1)c1F Chemical compound NCc(cc(CN1CCC1)cc1)c1F PFEQBDPYUCBUMS-UHFFFAOYSA-N 0.000 description 1
- LMIMLZKMTDETAN-UHFFFAOYSA-N NCc1c(CN2CCC2)c(F)ccc1F Chemical compound NCc1c(CN2CCC2)c(F)ccc1F LMIMLZKMTDETAN-UHFFFAOYSA-N 0.000 description 1
- MSSMFVLLLAGOIW-UHFFFAOYSA-N NCc1c(CN2CCCC2)cccc1F Chemical compound NCc1c(CN2CCCC2)cccc1F MSSMFVLLLAGOIW-UHFFFAOYSA-N 0.000 description 1
- KLNUEWISUIZSAF-OAHLLOKOSA-N N[C@@H](c(c(F)c1)ccc1F)Nc(cc(c(S(Nc1ncc[s]1)(=O)=O)c1)F)c1Cl Chemical compound N[C@@H](c(c(F)c1)ccc1F)Nc(cc(c(S(Nc1ncc[s]1)(=O)=O)c1)F)c1Cl KLNUEWISUIZSAF-OAHLLOKOSA-N 0.000 description 1
- ZITIXQVNSDDSCC-OAQYLSRUSA-N N[C@@H](c(cc(CCN1CCC1)cc1)c1F)Nc(c(Cl)c1)cc(F)c1S(Nc1c[s]cn1)(=O)=O Chemical compound N[C@@H](c(cc(CCN1CCC1)cc1)c1F)Nc(c(Cl)c1)cc(F)c1S(Nc1c[s]cn1)(=O)=O ZITIXQVNSDDSCC-OAQYLSRUSA-N 0.000 description 1
- VUZPRKDRMGTDPR-OAHLLOKOSA-N N[C@@H](c(cc1)ccc1F)Nc(c(Cl)c1)cc(F)c1S(Nc1ncc[s]1)(=O)=O Chemical compound N[C@@H](c(cc1)ccc1F)Nc(c(Cl)c1)cc(F)c1S(Nc1ncc[s]1)(=O)=O VUZPRKDRMGTDPR-OAHLLOKOSA-N 0.000 description 1
- UCTCAPHIYRCRBD-QGZVFWFLSA-N N[C@@H](c1cc(Cl)ccc1F)Nc(cc(c(S(Nc1nccnc1)(=O)=O)c1)F)c1Cl Chemical compound N[C@@H](c1cc(Cl)ccc1F)Nc(cc(c(S(Nc1nccnc1)(=O)=O)c1)F)c1Cl UCTCAPHIYRCRBD-QGZVFWFLSA-N 0.000 description 1
- YQRZDAJDAXUIGO-OAHLLOKOSA-N N[C@@H](c1cc(F)ccc1)Nc(cc(c(S(Nc1ncc[s]1)(=O)=O)c1)F)c1Cl Chemical compound N[C@@H](c1cc(F)ccc1)Nc(cc(c(S(Nc1ncc[s]1)(=O)=O)c1)F)c1Cl YQRZDAJDAXUIGO-OAHLLOKOSA-N 0.000 description 1
- WULALIPUNYGANZ-MRXNPFEDSA-N N[C@@H](c1ccccc1Cl)Nc(cc(c(S(Nc1nc(C(F)(F)F)ncc1)(=O)=O)c1)F)c1Cl Chemical compound N[C@@H](c1ccccc1Cl)Nc(cc(c(S(Nc1nc(C(F)(F)F)ncc1)(=O)=O)c1)F)c1Cl WULALIPUNYGANZ-MRXNPFEDSA-N 0.000 description 1
- UMXPGDDMIOQWNR-OAHLLOKOSA-N N[C@@H](c1ccccc1F)Nc(cc1F)cc(F)c1S(Nc1ncc[s]1)(=O)=O Chemical compound N[C@@H](c1ccccc1F)Nc(cc1F)cc(F)c1S(Nc1ncc[s]1)(=O)=O UMXPGDDMIOQWNR-OAHLLOKOSA-N 0.000 description 1
- NYNRZRXJNHIAJY-UHFFFAOYSA-N O=C(C(F)(F)F)c1cc(Cl)ccc1F Chemical compound O=C(C(F)(F)F)c1cc(Cl)ccc1F NYNRZRXJNHIAJY-UHFFFAOYSA-N 0.000 description 1
- LEVGQGNBKPLAOQ-UHFFFAOYSA-N O=S(c(c(F)c(c(NCc1c(CN2CCC2)cccc1F)c1)Cl)c1F)(Nc1c[s]cn1)=O Chemical compound O=S(c(c(F)c(c(NCc1c(CN2CCC2)cccc1F)c1)Cl)c1F)(Nc1c[s]cn1)=O LEVGQGNBKPLAOQ-UHFFFAOYSA-N 0.000 description 1
- WMZBZYXATSTGOK-GOSISDBHSA-N O=S(c(c(F)c1)cc(Cl)c1N[C@H](CN1CCC1)c1ccccc1)(Nc1ncc[s]1)=O Chemical compound O=S(c(c(F)c1)cc(Cl)c1N[C@H](CN1CCC1)c1ccccc1)(Nc1ncc[s]1)=O WMZBZYXATSTGOK-GOSISDBHSA-N 0.000 description 1
- AEWUIISQQKYDHY-UHFFFAOYSA-N O=S(c(c(F)c1)cc(Cl)c1OC(CC1)c2c1c(C(F)(F)F)ccc2)(Nc1c[s]cn1)=O Chemical compound O=S(c(c(F)c1)cc(Cl)c1OC(CC1)c2c1c(C(F)(F)F)ccc2)(Nc1c[s]cn1)=O AEWUIISQQKYDHY-UHFFFAOYSA-N 0.000 description 1
- UNDVMSCKJIZTDA-UHFFFAOYSA-N O=S(c(c(F)cc(NCc1c(CN2CCC2)cccc1Cl)c1)c1F)(Nc1c[s]cn1)=O Chemical compound O=S(c(c(F)cc(NCc1c(CN2CCC2)cccc1Cl)c1)c1F)(Nc1c[s]cn1)=O UNDVMSCKJIZTDA-UHFFFAOYSA-N 0.000 description 1
- AOUOXVRUVHWWCP-UHFFFAOYSA-N O=S(c(c(F)cc(NCc1c(CN2CCC2)cccc1F)c1)c1F)(Nc1nnccc1)=O Chemical compound O=S(c(c(F)cc(NCc1c(CN2CCC2)cccc1F)c1)c1F)(Nc1nnccc1)=O AOUOXVRUVHWWCP-UHFFFAOYSA-N 0.000 description 1
- YZADLKFWIOPPQZ-UHFFFAOYSA-N O=S(c(c(F)cc(NCc1cc(CN2CCC2)ccc1F)c1)c1F)(Nc1c[s]cn1)=O Chemical compound O=S(c(c(F)cc(NCc1cc(CN2CCC2)ccc1F)c1)c1F)(Nc1c[s]cn1)=O YZADLKFWIOPPQZ-UHFFFAOYSA-N 0.000 description 1
- CVAREDHYHXJFFV-UHFFFAOYSA-N O=S(c(cc(c(NC1Cc2cccnc2CC1)c1)Cl)c1F)(Nc1ncc[s]1)=O Chemical compound O=S(c(cc(c(NC1Cc2cccnc2CC1)c1)Cl)c1F)(Nc1ncc[s]1)=O CVAREDHYHXJFFV-UHFFFAOYSA-N 0.000 description 1
- VVQNYDYIEOFQKO-UHFFFAOYSA-N O=S(c(cc(c(NCc1c2[nH]ncc2ccc1F)c1)Cl)c1F)(Nc1c[s]cn1)=O Chemical compound O=S(c(cc(c(NCc1c2[nH]ncc2ccc1F)c1)Cl)c1F)(Nc1c[s]cn1)=O VVQNYDYIEOFQKO-UHFFFAOYSA-N 0.000 description 1
- DTZYTEAEVOGNSD-UHFFFAOYSA-N O=S(c(cc1Cl)ccc1NC1(CCC1)c1ccccc1)(Nc1ncc[s]1)=O Chemical compound O=S(c(cc1Cl)ccc1NC1(CCC1)c1ccccc1)(Nc1ncc[s]1)=O DTZYTEAEVOGNSD-UHFFFAOYSA-N 0.000 description 1
- FJAIGVDLJVDURQ-UHFFFAOYSA-N O=S(c(ccc(NCc1c(CN2CCC2)cccc1F)c1Cl)c1F)(Nc1c[s]cn1)=O Chemical compound O=S(c(ccc(NCc1c(CN2CCC2)cccc1F)c1Cl)c1F)(Nc1c[s]cn1)=O FJAIGVDLJVDURQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/69—Benzenesulfonamido-pyrimidines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
- C07D261/16—Benzene-sulfonamido isoxazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/48—Nitrogen atoms not forming part of a nitro radical
- C07D263/50—Benzene-sulfonamido oxazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
- C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/50—Nitrogen atoms bound to hetero atoms
- C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D451/06—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662432169P | 2016-12-09 | 2016-12-09 | |
| US62/432,169 | 2016-12-09 | ||
| PCT/US2017/033666 WO2018106284A1 (en) | 2016-12-09 | 2017-05-19 | Benzenesulfonamide compounds and their use as therapeutic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20190086772A true KR20190086772A (ko) | 2019-07-23 |
Family
ID=62488471
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020197019389A Abandoned KR20190086772A (ko) | 2016-12-09 | 2017-05-19 | 벤젠술폰아미드 화합물 및 치료제로서의 그의 용도 |
Country Status (18)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017201468A1 (en) | 2016-05-20 | 2017-11-23 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
| EP3551626B1 (en) | 2016-12-09 | 2023-10-25 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
| AU2019285184B2 (en) | 2018-06-13 | 2023-11-16 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
| US10981905B2 (en) * | 2018-08-31 | 2021-04-20 | Xenon Pharmaceuticals Inc. | Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents |
| MA53488A (fr) * | 2018-08-31 | 2021-12-08 | Xenon Pharmaceuticals Inc | Composés de sulfonamide substitués par hétéroaryle et leur utilisation en tant qu'inhibiteurs de canaux sodiques |
| CN111285825B (zh) * | 2018-12-10 | 2023-02-17 | 中国科学院上海药物研究所 | 一类苯磺酰胺取代的衍生物,其制法及其用途 |
| JP2023503343A (ja) | 2019-11-26 | 2023-01-27 | プラクシス プレシジョン メディシンズ, インコーポレイテッド | イオンチャネルモジュレーター |
| CN112125838B (zh) * | 2020-08-31 | 2021-07-27 | 浙江工业大学 | 一种三氟甲基化苯胺类化合物及其应用 |
| WO2023028056A1 (en) | 2021-08-24 | 2023-03-02 | Genentech, Inc. | 3-amino piperidyl sodium channel inhibitors |
| CN113698357A (zh) * | 2021-09-29 | 2021-11-26 | 守恒(厦门)医疗科技有限公司 | 磺胺嘧啶类衍生物及其在抗肿瘤药物的应用 |
| CN113861130A (zh) * | 2021-09-29 | 2021-12-31 | 守恒(厦门)医疗科技有限公司 | 联苯磺胺噻二唑类衍生物及其在抗肿瘤药物的应用 |
| AR133184A1 (es) * | 2023-07-07 | 2025-09-03 | Novartis Ag | Bloqueadores de canales de sodio |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US5877193A (en) | 1996-07-19 | 1999-03-02 | Hoffmann-La Roche Inc. | Use of N-(4-aryl-thiazol-2-yl)-sulfonamides |
| AU741482B2 (en) | 1997-05-07 | 2001-11-29 | Allergan Pharmaceuticals International Limited | Intravaginal drug delivery devices for the administration of testosterone and testosterone precursors |
| CA2349832A1 (en) | 1999-01-13 | 2000-07-20 | Warner-Lambert Company | Benzenesulfonamide derivatives and their use as mek inhibitors |
| ATE250932T1 (de) | 1999-07-16 | 2003-10-15 | Warner Lambert Co | Verfahren zur behandlung von chronischem schmerz durch verabreichung von einem mek hemmer |
| GB9928568D0 (en) | 1999-12-03 | 2000-02-02 | Zeneca Ltd | Chemical compounds |
| FR2836917B1 (fr) | 2002-03-11 | 2006-02-24 | Lipha | Derives nitroso de la diphenylamine, compositions pharmaceutiques les contenant en tant que medicaments utilisables dans le traitement des pathologies caracterisees par une situation de stress oxydatif |
| CA2744893A1 (en) | 2002-06-27 | 2004-01-08 | Novo Nordisk A/S | Aryl carbonyl derivatives as glucokinase activators |
| WO2004092123A2 (en) * | 2003-04-10 | 2004-10-28 | Microbia, Inc. | Inhibitors of fungal invasion |
| WO2005000309A2 (en) | 2003-06-27 | 2005-01-06 | Ionix Pharmaceuticals Limited | Chemical compounds |
| CA2531418A1 (en) | 2003-07-08 | 2005-01-20 | Novartis Ag | Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds |
| KR20060073930A (ko) | 2003-08-08 | 2006-06-29 | 버텍스 파마슈티칼스 인코포레이티드 | 통증 치료시 나트륨 또는 칼슘 채널 차단제로서 유용한헤테로아릴아미노설포닐페닐 유도체 |
| WO2006066109A2 (en) * | 2004-12-17 | 2006-06-22 | Takeda San Diego, Inc. | Hydroxysteroid dehydrogenase inhibitors |
| GB0510139D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
| WO2007039171A1 (en) | 2005-10-06 | 2007-04-12 | Sanofi-Aventis | 4-oxy-n-[1 ,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals |
| WO2007075895A2 (en) | 2005-12-21 | 2007-07-05 | Vertex Pharmaceuticals Incorporated | Heterocyclic derivatives as modulators of ion channels |
| KR101117931B1 (ko) | 2006-08-15 | 2012-04-12 | 에프. 호프만-라 로슈 아게 | 페닐, 피리딘 및 퀴놀린 유도체 |
| RU2474582C2 (ru) | 2006-10-19 | 2013-02-10 | СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Гетероарильные соединения, их композиции и их применение в качестве ингибиторов протеинкиназы |
| JP5460589B2 (ja) * | 2007-07-13 | 2014-04-02 | アイカジェン, インコーポレイテッド | ナトリウムチャネル阻害物質 |
| US8853250B2 (en) * | 2007-07-13 | 2014-10-07 | Icagen, Inc. | Sodium channel inhibitors |
| WO2009013171A2 (en) | 2007-07-24 | 2009-01-29 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
| NZ588983A (en) | 2008-06-25 | 2011-11-25 | Daiichi Sankyo Co Ltd | Carboxylic acid compound |
| EP2307412A2 (en) | 2008-07-01 | 2011-04-13 | Vertex Pharmaceuticals Incorporated | Heterocyclic derivatives as modulators of ion channels |
| US20110294853A1 (en) | 2008-09-12 | 2011-12-01 | Benjamin Pelcman | Bis Aromatic Compounds for Use in the Treatment of Inflammation |
| CA2747419C (en) * | 2009-01-12 | 2014-07-08 | Icagen, Inc. | Sulfonamide derivatives |
| WO2012004743A1 (en) | 2010-07-09 | 2012-01-12 | Pfizer Limited | Benzenesulfonamides useful as sodium channel inhibitors |
| BR112013003864B1 (pt) | 2010-08-20 | 2021-08-31 | Hutchison Medipharma Limited | Compostos de pirrolpirimidina, composição e uso dos mesmos |
| AU2012296529A1 (en) | 2011-08-17 | 2014-02-20 | Amgen Inc. | Heteroaryl sodium channel inhibitors |
| AU2012328561A1 (en) | 2011-10-28 | 2014-04-17 | Merck Sharp & Dohme Corp. | Benzoxazolinone compounds with selective activity in voltage-gated sodium channels |
| ES2586213T3 (es) * | 2011-10-31 | 2016-10-13 | Xenon Pharmaceuticals Inc. | Compuestos de bencenosulfonamida y su uso como agentes terapéuticos |
| MX2014005304A (es) * | 2011-10-31 | 2015-03-20 | Xenon Pharmaceuticals Inc | Biaril eter sulfonamidas y su uso como agentes terapeuticos. |
| US8889741B2 (en) * | 2012-02-09 | 2014-11-18 | Daiichi Sankyo Company, Limited | Cycloalkane derivatives |
| WO2013122897A1 (en) | 2012-02-13 | 2013-08-22 | Amgen Inc. | Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors |
| CA2874621A1 (en) | 2012-05-22 | 2013-11-28 | Genentech, Inc. | N-substituted benzamides and their use in the treatment of pain |
| US9376429B2 (en) * | 2012-10-15 | 2016-06-28 | Daewoong Pharmaceutical Co., Ltd. | Sodium channel blockers, preparation method thereof and use thereof |
| JP2015535251A (ja) | 2012-10-26 | 2015-12-10 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | 電位作動型ナトリウムチャネルにおいて選択的活性を有するベンゾオキサゾリノン化合物 |
| AU2013334664A1 (en) | 2012-10-26 | 2015-05-07 | Merck Sharp & Dohme Corp. | N-substituted indazole sulfonamide compounds with selective activity in voltage-gated sodium channels |
| TW201443025A (zh) * | 2013-04-19 | 2014-11-16 | Pfizer Ltd | 化學化合物 |
| TW201512171A (zh) * | 2013-04-19 | 2015-04-01 | Pfizer Ltd | 化學化合物 |
| US9212182B2 (en) | 2013-06-12 | 2015-12-15 | Amgen Inc. | Bicyclic sulfonamide compounds as sodium channel inhibitors |
| GB201310542D0 (en) | 2013-06-13 | 2013-07-31 | Antabio Sas | Compounds |
| WO2015035278A1 (en) | 2013-09-09 | 2015-03-12 | Bristol-Myers Squibb Company | RORγ MODULATORS |
| CN105611923B (zh) | 2013-09-10 | 2019-08-23 | 卓莫赛尔公司 | 用于治疗疼痛和糖尿病的钠通道调节剂 |
| JP6383418B2 (ja) | 2013-11-27 | 2018-08-29 | ジェネンテック, インコーポレイテッド | 置換ベンズアミド及びその使用方法 |
| WO2015077905A1 (en) | 2013-11-29 | 2015-06-04 | Merck Sharp & Dohme Corp. | Bicycloamine-substituted-n-benzenesulfonamide compounds with selective activity in voltage-gated sodium channels |
| CA2934473C (en) * | 2013-12-23 | 2019-08-20 | Purdue Pharma L.P. | Indazoles and use thereof |
| CN106795149B (zh) * | 2015-05-05 | 2019-09-24 | 上海海雁医药科技有限公司 | 双环取代的苯磺酰胺衍生物、其制法与医药上的用途 |
| BR112018012408A2 (pt) | 2015-12-18 | 2018-12-04 | Merck Sharp & Dohme | ?composto, composição, e, método para tratar um distúrbio de dor ou distúrbio de tosse ou de coceira aguda ou de coceira crônica? |
| US10442778B2 (en) * | 2016-03-22 | 2019-10-15 | Merck Sharp & Dohme Corp. | N1-phenylpropane-1,2-diamine compounds with selective activity in voltage-gated sodium channels |
| WO2017201468A1 (en) | 2016-05-20 | 2017-11-23 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
| ES2897998T3 (es) * | 2016-10-27 | 2022-03-03 | Bristol Myers Squibb Co | Inhibidores de la acilsulfonamida del NaV1.7 |
| US10968210B2 (en) * | 2016-11-17 | 2021-04-06 | Merck Sharp & Dohme Corp. | Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels |
| EP3551626B1 (en) | 2016-12-09 | 2023-10-25 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
| AU2019285184B2 (en) | 2018-06-13 | 2023-11-16 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
| MA53488A (fr) | 2018-08-31 | 2021-12-08 | Xenon Pharmaceuticals Inc | Composés de sulfonamide substitués par hétéroaryle et leur utilisation en tant qu'inhibiteurs de canaux sodiques |
| US10981905B2 (en) | 2018-08-31 | 2021-04-20 | Xenon Pharmaceuticals Inc. | Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents |
-
2017
- 2017-05-19 EP EP17728326.4A patent/EP3551626B1/en active Active
- 2017-05-19 SG SG10201912376VA patent/SG10201912376VA/en unknown
- 2017-05-19 AU AU2017371674A patent/AU2017371674B2/en active Active
- 2017-05-19 US US15/600,612 patent/US20180162868A1/en not_active Abandoned
- 2017-05-19 WO PCT/US2017/033666 patent/WO2018106284A1/en not_active Ceased
- 2017-05-19 TN TNP/2019/000175A patent/TN2019000175A1/en unknown
- 2017-05-19 RU RU2019120812A patent/RU2760303C2/ru active
- 2017-05-19 ES ES17728326T patent/ES2967410T3/es active Active
- 2017-05-19 SG SG10201912372XA patent/SG10201912372XA/en unknown
- 2017-05-19 MA MA048583A patent/MA48583A/fr unknown
- 2017-05-19 JP JP2019530725A patent/JP7022751B2/ja active Active
- 2017-05-19 BR BR112019011121A patent/BR112019011121A2/pt not_active IP Right Cessation
- 2017-05-19 KR KR1020197019389A patent/KR20190086772A/ko not_active Abandoned
- 2017-05-19 CN CN201780085678.6A patent/CN110325531B/zh active Active
- 2017-05-19 MX MX2019006697A patent/MX2019006697A/es unknown
-
2019
- 2019-05-15 PH PH12019501074A patent/PH12019501074A1/en unknown
- 2019-05-28 CO CONC2019/0005552A patent/CO2019005552A2/es unknown
- 2019-05-31 CL CL2019001481A patent/CL2019001481A1/es unknown
- 2019-06-06 IL IL267143A patent/IL267143A/en unknown
-
2020
- 2020-03-02 US US16/805,895 patent/US11174268B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US11174268B2 (en) | 2021-11-16 |
| EP3551626B1 (en) | 2023-10-25 |
| EP3551626A1 (en) | 2019-10-16 |
| SG10201912376VA (en) | 2020-02-27 |
| MX2019006697A (es) | 2019-08-16 |
| IL267143A (en) | 2019-08-29 |
| BR112019011121A2 (pt) | 2019-10-01 |
| SG10201912372XA (en) | 2020-02-27 |
| TN2019000175A1 (en) | 2020-10-05 |
| AU2017371674A1 (en) | 2019-05-23 |
| WO2018106284A1 (en) | 2018-06-14 |
| PH12019501074A1 (en) | 2019-08-19 |
| CA3042004A1 (en) | 2018-06-14 |
| RU2019120812A3 (cg-RX-API-DMAC7.html) | 2021-01-12 |
| CN110325531B (zh) | 2022-05-27 |
| ES2967410T3 (es) | 2024-04-30 |
| EP3551626C0 (en) | 2023-10-25 |
| MA48583A (fr) | 2021-04-21 |
| JP7022751B2 (ja) | 2022-02-18 |
| JP2019536810A (ja) | 2019-12-19 |
| US20210171537A1 (en) | 2021-06-10 |
| CL2019001481A1 (es) | 2019-08-09 |
| RU2019120812A (ru) | 2021-01-12 |
| US20180162868A1 (en) | 2018-06-14 |
| AU2017371674B2 (en) | 2021-07-22 |
| CN110325531A (zh) | 2019-10-11 |
| RU2760303C2 (ru) | 2021-11-23 |
| CO2019005552A2 (es) | 2019-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2017371674B2 (en) | Benzenesulfonamide compounds and their use as therapeutic agents | |
| US11299490B2 (en) | Benzenesulfonamide compounds and their use as therapeutic agents | |
| JP7450606B2 (ja) | ヘテロアリール置換スルホンアミド化合物および治療剤としてのそれらの使用 | |
| JP2021528387A (ja) | ベンゼンスルホンアミド化合物および治療剤としてのその使用 | |
| JP2021535137A (ja) | ヘテロアリール置換スルホンアミド化合物、およびナトリウムチャネル阻害剤としてのその使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20190704 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20200507 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20211031 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20220527 |
|
| NORF | Unpaid initial registration fee | ||
| PC1904 | Unpaid initial registration fee |